AMN Healthcare Services
- Market cap
- 1.41B
- P/E (TTM)i
- 13.58
- P/Bi
- 1.91
- EPSi
- -2.48
- Div yieldi
- 0.00%
- 52W posi
- 92%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Medical Care Facilities
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| AMN Healthcare Services (AMN) | 1.41B | 13.58 | 1.91 | 0.00% |
| HCA Healthcare (HCA) | 95.08B | 14.73 | -14.32 | 0.68% |
| Tenet Healthcare (THC) | 20.92B | 10.04 | 4.49 | 0.00% |
| Encompass Health (EHC) | 12.08B | 19.95 | 4.65 | 0.62% |
| DaVita (DVA) | 11.28B | 14.57 | -14.74 | 0.00% |
| Fresenius Medical Care (FMS) | 11.01B | 11.14 | 0.78 | 4.13% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 2.2% above Morningstar's fair value estimate.
Fair value
AMN Healthcare Services Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 3% premium over our quantitative fair value estimate of $35.72 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The company's unfavorable dividend structure decreases our fair value estimate. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. For example, the firm's forward dividend yield of 0% falls in the bottom 30% compared with global peers. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are expensive.
Conversely, the firm's valuation metrics are reassuring. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.3, a core component of valuation, ranks in the top 40% globally. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-08 07:21:14 · For reference only, not investment advice and not tailored to your situation.